Alastair D. Burt
YOU?
Author Swipe
View article: Investigating the mechanisms of indocyanine green tumour uptake in sarcoma cell lines and <i>ex vivo</i> human tissue
Investigating the mechanisms of indocyanine green tumour uptake in sarcoma cell lines and <i>ex vivo</i> human tissue Open
Indocyanine green (ICG) is a well‐established near‐infrared dye which has been used clinically for several decades. Recently, it has been utilised for fluorescence‐guided surgery in a range of solid cancer types, including sarcoma, with th…
View article: AI-based automation of enrollment criteria and endpoint assessment in clinical trials in liver diseases
AI-based automation of enrollment criteria and endpoint assessment in clinical trials in liver diseases Open
Clinical trials in metabolic dysfunction-associated steatohepatitis (MASH, formerly known as nonalcoholic steatohepatitis) require histologic scoring for assessment of inclusion criteria and endpoints. However, variability in interpretatio…
View article: Severe acute liver disease in adults: Contemporary role of histopathology
Severe acute liver disease in adults: Contemporary role of histopathology Open
Liver biopsies have consistently contributed to our understanding of the pathogenesis and aetiologies of acute liver disease. As other diagnostic modalities have been developed and refined, the role of biopsy in the management of patients …
View article: Serum ferritin levels can predict long-term outcomes in patients with metabolic dysfunction-associated steatotic liver disease
Serum ferritin levels can predict long-term outcomes in patients with metabolic dysfunction-associated steatotic liver disease Open
Objective Hyperferritinaemia is associated with liver fibrosis severity in patients with metabolic dysfunction-associated steatotic liver disease (MASLD), but the longitudinal implications have not been thoroughly investigated. We assessed…
View article: AI-based histologic scoring enables automated and reproducible assessment of enrollment criteria and endpoints in NASH clinical trials
AI-based histologic scoring enables automated and reproducible assessment of enrollment criteria and endpoints in NASH clinical trials Open
Clinical trials in nonalcoholic steatohepatitis (NASH) require histologic scoring for assessment of inclusion criteria and endpoints. However, guidelines for scoring key features have led to variability in interpretation, impacting clinica…
View article: An end-to-end platform for digital pathology using hyperspectral autofluorescence microscopy and deep learning based virtual histology
An end-to-end platform for digital pathology using hyperspectral autofluorescence microscopy and deep learning based virtual histology Open
Conventional histopathology involves expensive and labor intensive processes that often consume tissue samples, rendering them unavailable for other analysis. We present a novel end-to-end workflow for pathology powered by hyperspectral mi…
View article: Data Supplement from DNA-PK—A Candidate Driver of Hepatocarcinogenesis and Tissue Biomarker That Predicts Response to Treatment and Survival
Data Supplement from DNA-PK—A Candidate Driver of Hepatocarcinogenesis and Tissue Biomarker That Predicts Response to Treatment and Survival Open
Data Supplement from DNA-PK—A Candidate Driver of Hepatocarcinogenesis and Tissue Biomarker That Predicts Response to Treatment and Survival
View article: Supplementary Figure Legends from DNA-PK—A Candidate Driver of Hepatocarcinogenesis and Tissue Biomarker That Predicts Response to Treatment and Survival
Supplementary Figure Legends from DNA-PK—A Candidate Driver of Hepatocarcinogenesis and Tissue Biomarker That Predicts Response to Treatment and Survival Open
Supplementary Figure Legends
View article: Supplementary Tables 1-2 from DNA-PK—A Candidate Driver of Hepatocarcinogenesis and Tissue Biomarker That Predicts Response to Treatment and Survival
Supplementary Tables 1-2 from DNA-PK—A Candidate Driver of Hepatocarcinogenesis and Tissue Biomarker That Predicts Response to Treatment and Survival Open
Supplementary Tables 1-2. Supplementary Table 1. Clinical features of the subset of patients receiving palliative TACE as first line therapy Supplementary Table 2 - Tumour Factors associated with survival in cohort two
View article: Supplementary Methods from DNA-PK—A Candidate Driver of Hepatocarcinogenesis and Tissue Biomarker That Predicts Response to Treatment and Survival
Supplementary Methods from DNA-PK—A Candidate Driver of Hepatocarcinogenesis and Tissue Biomarker That Predicts Response to Treatment and Survival Open
Supplementary Methods
View article: Supplementary Tables 1-2 from DNA-PK—A Candidate Driver of Hepatocarcinogenesis and Tissue Biomarker That Predicts Response to Treatment and Survival
Supplementary Tables 1-2 from DNA-PK—A Candidate Driver of Hepatocarcinogenesis and Tissue Biomarker That Predicts Response to Treatment and Survival Open
Supplementary Tables 1-2. Supplementary Table 1. Clinical features of the subset of patients receiving palliative TACE as first line therapy Supplementary Table 2 - Tumour Factors associated with survival in cohort two
View article: Supplementary Figures 1-11 from DNA-PK—A Candidate Driver of Hepatocarcinogenesis and Tissue Biomarker That Predicts Response to Treatment and Survival
Supplementary Figures 1-11 from DNA-PK—A Candidate Driver of Hepatocarcinogenesis and Tissue Biomarker That Predicts Response to Treatment and Survival Open
Supplementary Figures 1-11. Supplementary Figure 1. DNA-PK expression and tumour specific PRKDC locus amplification Supplementary Figure 2. DDR gene expression in HCC cells Supplementary Figure 3: DDR protein expression and activity in HCC…
View article: Data from DNA-PK—A Candidate Driver of Hepatocarcinogenesis and Tissue Biomarker That Predicts Response to Treatment and Survival
Data from DNA-PK—A Candidate Driver of Hepatocarcinogenesis and Tissue Biomarker That Predicts Response to Treatment and Survival Open
Purpose: Therapy resistance and associated liver disease make hepatocellular carcinomas (HCC) difficult to treat with traditional cytotoxic therapies, whereas newer targeted approaches offer only modest survival benefit. We focused on DNA-…
View article: Supplementary Figure Legends from DNA-PK—A Candidate Driver of Hepatocarcinogenesis and Tissue Biomarker That Predicts Response to Treatment and Survival
Supplementary Figure Legends from DNA-PK—A Candidate Driver of Hepatocarcinogenesis and Tissue Biomarker That Predicts Response to Treatment and Survival Open
Supplementary Figure Legends
View article: Data Supplement from DNA-PK—A Candidate Driver of Hepatocarcinogenesis and Tissue Biomarker That Predicts Response to Treatment and Survival
Data Supplement from DNA-PK—A Candidate Driver of Hepatocarcinogenesis and Tissue Biomarker That Predicts Response to Treatment and Survival Open
Data Supplement from DNA-PK—A Candidate Driver of Hepatocarcinogenesis and Tissue Biomarker That Predicts Response to Treatment and Survival
View article: Supplementary Figures 1-11 from DNA-PK—A Candidate Driver of Hepatocarcinogenesis and Tissue Biomarker That Predicts Response to Treatment and Survival
Supplementary Figures 1-11 from DNA-PK—A Candidate Driver of Hepatocarcinogenesis and Tissue Biomarker That Predicts Response to Treatment and Survival Open
Supplementary Figures 1-11. Supplementary Figure 1. DNA-PK expression and tumour specific PRKDC locus amplification Supplementary Figure 2. DDR gene expression in HCC cells Supplementary Figure 3: DDR protein expression and activity in HCC…
View article: Data from DNA-PK—A Candidate Driver of Hepatocarcinogenesis and Tissue Biomarker That Predicts Response to Treatment and Survival
Data from DNA-PK—A Candidate Driver of Hepatocarcinogenesis and Tissue Biomarker That Predicts Response to Treatment and Survival Open
Purpose: Therapy resistance and associated liver disease make hepatocellular carcinomas (HCC) difficult to treat with traditional cytotoxic therapies, whereas newer targeted approaches offer only modest survival benefit. We focused on DNA-…
View article: Supplementary Methods from DNA-PK—A Candidate Driver of Hepatocarcinogenesis and Tissue Biomarker That Predicts Response to Treatment and Survival
Supplementary Methods from DNA-PK—A Candidate Driver of Hepatocarcinogenesis and Tissue Biomarker That Predicts Response to Treatment and Survival Open
Supplementary Methods
View article: Survey of liver pathologists to assess attitudes towards digital pathology and artificial intelligence
Survey of liver pathologists to assess attitudes towards digital pathology and artificial intelligence Open
Aims A survey of members of the UK Liver Pathology Group (UKLPG) was conducted, comprising consultant histopathologists from across the UK who report liver specimens and participate in the UK National Liver Pathology External Quality Assur…
View article: COVID-19 and liver cancer: lost patients and larger tumours
COVID-19 and liver cancer: lost patients and larger tumours Open
Background Northern England has been experiencing a persistent rise in the number of primary liver cancers, largely driven by an increasing incidence of hepatocellular carcinoma (HCC) secondary to alcohol-related liver disease and non-alco…
View article: Sulfatase-2 from Cancer Associated Fibroblasts: An Environmental Target for Hepatocellular Carcinoma?
Sulfatase-2 from Cancer Associated Fibroblasts: An Environmental Target for Hepatocellular Carcinoma? Open
Introduction: Heparin sulphate proteoglycans in the liver tumour microenvironment (TME) are key regulators of cell signalling, modulated by sulfatase-2 (SULF2). SULF2 overexpression occurs in hepatocellular carcinoma (HCC). Our aims were t…